title: How Octogenarians with Bladder Cancer Are Treated in a Maximum-Care Hospital: The Real-Life Experience.
abstract: BACKGROUND
  With increasing life expectancy, curative treatment of octogenarians with urothelial carcinoma of the bladder (UCB) becomes more important.
  
  
  METHODS
  The treatment modalities of 276 octogenarians with UCB who were treated at the University Hospital of Erlangen between 1982 and 2011 were assessed retrospectively.
  
  
  RESULTS
  One hundred forty-six patients had non-muscle invasive bladder cancer (NMIBC) while 71 had muscle invasive bladder cancer (MIBC). No data was available for 59 patients. Eighty-five (58.2%) of the 146 patients with NMIBC received transurethral resection of the bladder tumor (TURBT) only, another 38 patients (26%) underwent additional intravesical therapy; and 8.9% were treated with radiochemotherapy (RCT), 4.1% with radiotherapy (RT), 1.4% with systemic chemotherapy and 1.4% with radical cystectomy (RC). Of the 71 patients suffering from MIBC, 39 (54.9%) received TURBT alone. A potentially curative therapy was performed on 31 of the 71 patients with MIBC (43.7%). Of these, 16 patients (51.6%) received RCT, 9 patients (29.0%) RT and 6 patients (19.4%) RC. In Kaplan-Meier analysis, patients with MIBC had better median overall survival with curative treatment compared to TURBT alone (28 vs. 9 months; p < 0.001, log-rank test).
  
  
  CONCLUSIONS
  By offering a wide range of treatment options, over 43% of octogenarians with MIBC received a curative therapy at a maximum care hospital.
authors.affiliation: Department of Urology, University Hospital Erlangen, Erlangen, Germany.
authors.forename: Danijel
authors.initials: D
authors.lastname: Sikic
authors.forename: Sven
authors.initials: S
authors.lastname: Wach
authors.forename: Helge
authors.initials: H
authors.lastname: Taubert
authors.forename: Mario
authors.initials: M
authors.lastname: Richterstetter
authors.forename: Frank
authors.initials: F
authors.lastname: Kunath
authors.forename: Verena
authors.initials: V
authors.lastname: Lieb
authors.forename: F Steffen
authors.initials: FS
authors.lastname: Krause
authors.forename: Ricarda
authors.initials: R
authors.lastname: Merten
authors.forename: Oliver
authors.initials: O
authors.lastname: Ott
authors.forename: Rainer
authors.initials: R
authors.lastname: Fietkau
authors.forename: Bernd
authors.initials: B
authors.lastname: Wullich
authors.forename: Bastian
authors.initials: B
authors.lastname: Keck
mesh_terms: D000369:Aged, 80 and over; D002277:Carcinoma / Q000601:surgery*; D015653:Cystectomy / Q000009:adverse effects / Q000379:methods*; D005500:Follow-Up Studies; D005853:Geriatrics / Q000379:methods; D006761:Hospitals; D006801:Humans; D053208:Kaplan-Meier Estimate; D008017:Life Expectancy; D009132:Muscles / Q000473:pathology; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D012189:Retrospective Studies; D012306:Risk; D000071077:Surgical Oncology / Q000379:methods; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000601:surgery* / Q000628:therapy*; D019459:Urothelium / Q000473:pathology / Q000601:surgery*